Chemo and immunotherapy before chemoradiation for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new combination of chemotherapy and immunotherapy before standard chemoradiation for locally advanced cervical cancer. The goal is to see if adding immunotherapy first helps shrink the tumor and improve treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have squamous cell cervical cancer that has not been treated before
- Your cancer is locally advanced (stage T3-4, N1-2, M0) but has not spread to distant organs
- You are healthy enough to carry out daily activities (ECOG score 0 or 1)
- Your blood counts and kidney/liver function are within acceptable ranges
- You do not have active hepatitis B or C, HIV, or other serious infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
This trial tests adding a new immunotherapy drug (cadonilimab) to standard chemotherapy before surgery for locally advanced cervical cancer. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
This trial tests whether combining chemotherapy with immunotherapy before surgery can help treat cervical cancer that is PD-L1 negative. It's for women with larger tumors (stage IB3 to IIB) who have not been treated yet.
This trial tests a new drug called Cardenimumab combined with standard chemotherapy and radiation for women with high-risk cervical cancer. The goal is to see if adding this drug can improve outcomes for patients whose tumors are large, have spread to lymph nodes, or are stage IV.
This trial tests combining standard chemoradiation with a PD-1 inhibitor (a drug that helps your immune system fight cancer) for advanced cervical cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatment alone.
Hear when a new Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.